Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

An update on the anxiolytic and neuroprotective properties of etifoxine: from brain GABA modulation to a whole-body mode of action.

Nuss P, Ferreri F, Bourin M.

Neuropsychiatr Dis Treat. 2019 Jul 3;15:1781-1795. doi: 10.2147/NDT.S200568. eCollection 2019. Review.

2.

[Organic and psychiatric intricacy: The complex psychiatric disorder concept, paraclinical investigations].

Ferreri F, Bourla A, Capron J, Quillerou B, Rossignol J, Borden A, Guechot J, Lamaziere A, Nuss P, Mekinian A, Mouchabac S.

Presse Med. 2019 Jun;48(6):609-624. doi: 10.1016/j.lpm.2019.04.017. Epub 2019 May 28. Review. French.

PMID:
31151849
3.

Measuring Progress towards a Circular Economy: A Monitoring Framework for Economy-wide Material Loop Closing in the EU28.

Mayer A, Haas W, Wiedenhofer D, Krausmann F, Nuss P, Blengini GA.

J Ind Ecol. 2019 Feb;23(1):62-76. doi: 10.1111/jiec.12809. Epub 2018 Sep 25.

4.

[The concerning attitudes and beliefs of nursing students toward antidepressants and depression].

Blanc JV, Lapidus N, Nuss P, Mouchabac S, Ferreri F.

Encephale. 2018 Jun;44(3):297-298. doi: 10.1016/j.encep.2017.10.003. Epub 2017 Dec 19. French. No abstract available.

PMID:
29273343
5.

Towards better monitoring of technology critical elements in Europe: Coupling of natural and anthropogenic cycles.

Nuss P, Blengini GA.

Sci Total Environ. 2018 Feb 1;613-614:569-578. doi: 10.1016/j.scitotenv.2017.09.117. Epub 2017 Sep 26.

6.

[Contemporary behavioural addictions, an overview and the nursing position].

Nuss P.

Soins. 2017 Jun;62(816):33-35. doi: 10.1016/j.soin.2017.04.008. Review. French.

7.

Membrane lipidomics in schizophrenia patients: a correlational study with clinical and cognitive manifestations.

Tessier C, Sweers K, Frajerman A, Bergaoui H, Ferreri F, Delva C, Lapidus N, Lamaziere A, Roiser JP, De Hert M, Nuss P.

Transl Psychiatry. 2016 Oct 4;6(10):e906. doi: 10.1038/tp.2016.142.

8.

Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg/day) and escitalopram (10-20mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study.

Udristoiu T, Dehelean P, Nuss P, Raba V, Picarel-Blanchot F, de Bodinat C.

J Affect Disord. 2016 Jul 15;199:6-12. doi: 10.1016/j.jad.2016.03.048. Epub 2016 Mar 26.

PMID:
27054610
9.

Deriving the Metal and Alloy Networks of Modern Technology.

Ohno H, Nuss P, Chen WQ, Graedel TE.

Environ Sci Technol. 2016 Apr 5;50(7):4082-90. doi: 10.1021/acs.est.5b05093. Epub 2016 Mar 16.

PMID:
26927531
10.

Structural Investigation of Aluminum in the U.S. Economy using Network Analysis.

Nuss P, Chen WQ, Ohno H, Graedel TE.

Environ Sci Technol. 2016 Apr 5;50(7):4091-101. doi: 10.1021/acs.est.5b05094. Epub 2016 Mar 15.

PMID:
26926990
11.

Building the Material Flow Networks of Aluminum in the 2007 U.S. Economy.

Chen WQ, Graedel TE, Nuss P, Ohno H.

Environ Sci Technol. 2016 Apr 5;50(7):3905-12. doi: 10.1021/acs.est.5b05095. Epub 2016 Mar 16.

PMID:
26926828
12.

Phospholipase A2-Induced Remodeling Processes on Liquid-Ordered/Liquid-Disordered Membranes Containing Docosahexaenoic or Oleic Acid: A Comparison Study.

Georgieva R, Mircheva K, Vitkova V, Balashev K, Ivanova T, Tessier C, Koumanov K, Nuss P, Momchilova A, Staneva G.

Langmuir. 2016 Feb 23;32(7):1756-70. doi: 10.1021/acs.langmuir.5b03317. Epub 2016 Feb 10.

PMID:
26794691
13.

Revisiting loxapine: a systematic review.

Popovic D, Nuss P, Vieta E.

Ann Gen Psychiatry. 2015 Apr 1;14:15. doi: 10.1186/s12991-015-0053-3. eCollection 2015.

14.

Criticality of metals and metalloids.

Graedel TE, Harper EM, Nassar NT, Nuss P, Reck BK.

Proc Natl Acad Sci U S A. 2015 Apr 7;112(14):4257-62. doi: 10.1073/pnas.1500415112. Epub 2015 Mar 23.

15.

Docosahexaenoic acid promotes micron scale liquid-ordered domains. A comparison study of docosahexaenoic versus oleic acid containing phosphatidylcholine in raft-like mixtures.

Georgieva R, Chachaty C, Hazarosova R, Tessier C, Nuss P, Momchilova A, Staneva G.

Biochim Biophys Acta. 2015 Jun;1848(6):1424-35. doi: 10.1016/j.bbamem.2015.02.027. Epub 2015 Mar 9.

16.

Anxiety disorders and GABA neurotransmission: a disturbance of modulation.

Nuss P.

Neuropsychiatr Dis Treat. 2015 Jan 17;11:165-75. doi: 10.2147/NDT.S58841. eCollection 2015. Review.

17.

Perceptual hysteresis as a marker of perceptual inflexibility in schizophrenia.

Martin JR, Dezecache G, Pressnitzer D, Nuss P, Dokic J, Bruno N, Pacherie E, Franck N.

Conscious Cogn. 2014 Nov;30:62-72. doi: 10.1016/j.concog.2014.07.014. Epub 2014 Aug 21.

PMID:
25147080
18.

Life cycle assessment of metals: a scientific synthesis.

Nuss P, Eckelman MJ.

PLoS One. 2014 Jul 7;9(7):e101298. doi: 10.1371/journal.pone.0101298. eCollection 2014.

19.

Criticality of iron and its principal alloying elements.

Nuss P, Harper EM, Nassar NT, Reck BK, Graedel TE.

Environ Sci Technol. 2014 Apr 1;48(7):4171-7. doi: 10.1021/es405044w. Epub 2014 Mar 24.

PMID:
24597917
20.

Comparative life cycle assessment (LCA) of construction and demolition (C&D) derived biomass and U.S. northeast forest residuals gasification for electricity production.

Nuss P, Gardner KH, Jambeck JR.

Environ Sci Technol. 2013 Apr 2;47(7):3463-71. doi: 10.1021/es304312f. Epub 2013 Mar 15.

PMID:
23496419
21.

[Who are patients suffering from bipolar disorders in France? The TEMPPO survey: patients' sociodemographic and clinical characteristics data].

de Carvalho W, Nuss P, Blin P, Arnaud R, Filipovics A, Loze JY, Dillenschneider A.

Encephale. 2012 Jun;38(3):211-23. doi: 10.1016/j.encep.2012.04.007. Epub 2012 Jun 5. French.

PMID:
22726409
22.

[Treatment practices in the management of patients with bipolar disorder in France. The TEMPPO study].

Nuss P, de Carvalho W, Blin P, Arnaud R, Filipovics A, Loze JY, Dillenschneider A.

Encephale. 2012 Feb;38(1):75-85. doi: 10.1016/j.encep.2011.11.002. Epub 2011 Dec 9. French.

PMID:
22381727
23.

The interaction of antipsychotic drugs with lipids and subsequent lipid reorganization investigated using biophysical methods.

Alves I, Staneva G, Tessier C, Salgado GF, Nuss P.

Biochim Biophys Acta. 2011 Aug;1808(8):2009-18. doi: 10.1016/j.bbamem.2011.02.021. Epub 2011 Mar 4.

24.

[Therapeutic strategy of depressive episodes. Prevention of relapse risk].

Nuss P.

Encephale. 2010 Dec;36 Suppl 5:S145-9. doi: 10.1016/S0013-7006(10)70048-8. Review. French.

PMID:
21211636
25.

Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride.

Nuss P, Tessier C.

Curr Med Res Opin. 2010 Apr;26(4):787-801. doi: 10.1185/03007990903576953. Review.

PMID:
20121655
26.

Liquid-liquid immiscibility under non-equilibrium conditions in a model membrane: an X-ray synchrotron study.

Tessier C, Staneva G, Trugnan G, Wolf C, Nuss P.

Colloids Surf B Biointerfaces. 2009 Nov 1;74(1):293-7. doi: 10.1016/j.colsurfb.2009.07.033. Epub 2009 Aug 3.

PMID:
19720510
27.

Abnormal transbilayer distribution of phospholipids in red blood cell membranes in schizophrenia.

Nuss P, Tessier C, Ferreri F, De Hert M, Peuskens J, Trugnan G, Masliah J, Wolf C.

Psychiatry Res. 2009 Sep 30;169(2):91-6. doi: 10.1016/j.psychres.2009.01.009. Epub 2009 Jul 30.

PMID:
19646766
28.

The use of amisulpride in the treatment of acute psychosis.

Nuss P, Hummer M, Tessier C.

Ther Clin Risk Manag. 2007 Mar;3(1):3-11.

29.

Modification of membrane heterogeneity by antipsychotic drugs: an X-ray diffraction comparative study.

Tessier C, Nuss P, Staneva G, Wolf C.

J Colloid Interface Sci. 2008 Apr 15;320(2):469-75. doi: 10.1016/j.jcis.2008.01.034. Epub 2008 Jan 31.

PMID:
18279883
30.

Two-year study of relapse prevention by a new education program in schizophrenic patients treated with the same antipsychotic drug.

Chabannes JP, Bazin N, Leguay D, Nuss P, Peretti CS, Tatu P, Hameg A, Garay RP, Ferreri M.

Eur Psychiatry. 2008 Jan;23(1):8-13. Epub 2007 Oct 26.

PMID:
17964764
31.

Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes.

Benyamina A, Arbus C, Nuss P, Garay RP, Neliat G, Hameg A.

Eur J Pharmacol. 2008 Jan 14;578(2-3):142-7. Epub 2007 Oct 2.

PMID:
17936750
32.

[Neurologic symptoms in schizophrenia].

Nuss P, Ferreri F, Agbokou C, Peretti CS.

Encephale. 2007 Jun;33 Pt 3:S392-4. doi: 10.1016/S0013-7006(07)74588-8. Review. French. No abstract available.

PMID:
19101357
33.

[Treatment of major depressive disorder. The place of residual symptoms: between remission and cure].

Nuss P.

Encephale. 2005 Dec;31 Pt 3:S14-6; discussion S17. French. No abstract available.

PMID:
16462637
34.

A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian).

Hodé Y, Reimold M, Demazières A, Reischl G, Bayle F, Nuss P, Hameg A, Dib M, Macher JP.

Psychopharmacology (Berl). 2005 Jul;180(2):377-84. Epub 2005 Mar 15.

PMID:
15948013
35.

The generic alternative in schizophrenia: opportunity or threat?

Nuss P, Taylor D, De Hert M, Hummer M.

CNS Drugs. 2004;18(12):769-75. Review.

PMID:
15377167
36.

Effects of stress and etifoxine on pentobarbital-induced loss of righting reflex in Balb/cByJ and C57BL/6J mice.

Verleye M, Heulard I, Nuss P, Gillardin JM.

Neurosci Lett. 2003 Dec 19;353(2):127-30.

PMID:
14664917
37.

Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine.

Peinado J, Hameg A, Garay RP, Bayle F, Nuss P, Dib M.

Naunyn Schmiedebergs Arch Pharmacol. 2003 Feb;367(2):134-9. Epub 2003 Jan 23.

PMID:
12595954
38.

Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes.

Hameg A, Bayle F, Nuss P, Dupuis P, Garay RP, Dib M.

Biochem Pharmacol. 2003 Feb 1;65(3):435-40.

PMID:
12527336
39.
40.

What is the schizophrenic patients' level of information about their disease and their treatment?

Ferreri M, Rouillon F, Nuss P, Bazin N, Farah S, Djaballah K, Gerard D.

Encephale. 2000 Oct;26 Spec No 1:15-22. English, French.

PMID:
11294058
41.

[What information do patients with schizophrenia have about their illness and treatment?].

Ferreri M, Rouillon F, Nuss P, Bazin N, Farah S, Djaballah K, Gerard D.

Encephale. 2000 Sep-Oct;26(5):30-8. French.

PMID:
11192802
42.

[When and how to stop anxiolytic drugs].

Nuss P.

Rev Prat. 1999 Sep 15;49(14 Suppl):S36-41. French.

PMID:
10887616
43.

[Dysthymic disorders].

Ferreri M, Morand P, Elatki S, Nuss P.

Rev Prat. 1999 Apr 1;49(7):717-22. French.

PMID:
10337215
44.

[Is the anxious patient dependent?].

Nuss P.

Encephale. 1998 May-Jun;24(3):260-6. Review. French.

PMID:
9696921
45.

Protein-polysaccharide complexes as surfactants.

Gurov AN, Nuss PV.

Nahrung. 1986;30(3-4):349-53.

PMID:
3748120
46.

[Physico-chemical properties of the complexes of bacitracin with DNA and its effect on the process of transcription in vitro].

Permogorov VI, Nuss PV, Lukin AA, Timokhina EA, Perel'man BV.

Mol Biol (Mosk). 1982 Nov-Dec;16(6):1245-52. Russian.

PMID:
7155141
47.

An ultrasound receiver with programmable time gain control.

Barnes RW, Nomeir AM, Pardue GT, Nuss PH.

J Clin Ultrasound. 1975 Jun;3(2):121-4.

PMID:
829498
48.

A standardization system that cuts corners in coding.

NUSS P.

Hosp Manage. 1963 Jan;95:32-40. No abstract available.

PMID:
13939259

Supplemental Content

Support Center